Kucers’ The Use of Antibiotics PDF Free Download

Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition

Kucers’ The Use of Antibiotics is the definitive, internationally-authored reference, providing everything that the infectious diseases specialist and prescriber needs to know about antimicrobials in this vast and rapidly developing field. The much-expanded Seventh Edition comprises 4800 pages in 3 volumes in order to cover all new and existing therapies, and emerging drugs not yet fully licensed. Concentrating on the treatment of infectious diseases, the content is divided into four sections – antibiotics, anti-fungal drugs, anti-parasitic drugs, and anti-viral drugs – and is highly structured for ease of reference.
Each chapter is organized in a consistent format, covering susceptibility, formulations and dosing (adult and pediatric), pharmacokinetics and pharmacodynamics, toxicity, and drug distribution, with detailed discussion regarding clinical uses – a feature unique to this title. Compiled by an expanded team of internationally renowned and respected editors, with expert contributors representing Europe, Africa, Asia, Australia, South America, the US, and Canada, the Seventh Edition adopts a truly global approach. It remains invaluable for anyone using antimicrobial agents in their clinical practice and provides, in a systematic and concise manner, all the information required when prescribing an antimicrobial to treat infection.

Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition

List Price:

$599.95 USD

New From:

$465.19 USD

Download Ebook pdf

Get it $20 USD

Kucers’encyclopedic report on the current status of virtually all antimicrobial agents is testimony to the extraordinary, un-ending progress in dealing with infectious diseases. Never theless, with unexplored or incompletely pursued opportunities, there are formidable challenges ahead. The most obvious new challenges and opportunities are antibiotic resistance, expanded pursuit of antiviral agents, the constant emergence of new infectious disease threats, and, possibly, manipulation of the microbiome.
A great advantage of most antimicrobial agents is that they are readily available, relatively inexpensive, usually short course, and generally well-tolerated. These advantages are also economic disincentives for new drug development. The laws of survival. Antimicrobial resistance has now reached a crisis stage with warnings for the “post-antibiotic era”. This problem was predicted in the 2006 publication Bad Bugs, Need Drugs(Talbot et al., 2006), but the concern was largely ignored by the medical community until it was declared a “crisis” a decade later by the CDC, WHO, and key world leaders, including President Obama (Institute of Medicine [US] Forum on Microbial Threats, 2010; Spellberg et al., 2008). 
The response to this crisis has been impressive in terms of new products for treatment of diverse infections, including those caused by resistant pathogens. For example, the number of new antibiotics approved by the FDA decreased to only one in the four year period of 2008–2012. This has increased dramatically to 10 new antibiotics in the last 4 years! (Gould and Bal, 2013). This progress has also included methods to dissuade antibiotic abuse with improved diagnostics, multiple evidence-based guidelines, new infection prevention methods, and new products to help distinguish bacterial vs. non-bacterial infections. In addition, the recent history of anti-infective development has expanded in multiple directions (Carlet et al., 20

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *